Dyadic Logo Current.jpg
Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference
02 janv. 2024 08h30 HE | Dyadic International, Inc.
JUPITER, Fla., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic Logo Current.jpg
Dyadic Attends Investor Events in December
30 nov. 2023 08h30 HE | Dyadic International, Inc.
Dyadic Attends Investor Events in December
Dyadic Logo Current.jpg
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
29 nov. 2023 08h30 HE | Dyadic International, Inc.
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
Dyadic Logo Current.jpg
Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa
20 nov. 2023 08h30 HE | Dyadic International, Inc.
JUPITER, Fla., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building...
Dyadic Logo Current.jpg
Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
08 nov. 2023 16h00 HE | Dyadic International, Inc.
Received an upfront payment of $0.6 million in October for product development and licensing of our Dapibus™ platform for animal-free dairy enzyme productsDYAI-100 Phase 1 clinical trial top-line...
Dyadic Logo Current.jpg
Dyadic to Present at Industry Events in November
30 oct. 2023 08h30 HE | Dyadic International, Inc.
Dyadic to Present at Industry Events in November
Dyadic Logo Current.jpg
Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
25 oct. 2023 16h30 HE | Dyadic International, Inc.
JUPITER, Fla., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Dyadic Logo Current.jpg
Dyadic Appoints Doug Pace to Its Executive Leadership Team
09 oct. 2023 08h30 HE | Dyadic International, Inc.
JUPITER, Fla., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Dyadic Logo Current.jpg
Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vaccines for Infectious Diseases
05 oct. 2023 08h30 HE | Dyadic International, Inc.
JUPITER, Fla., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Dyadic Logo Current.jpg
Dyadic to Present at Industry and Investor Events in October
29 sept. 2023 08h30 HE | Dyadic International, Inc.
Dyadic to Present at Industry and Investor Events in October